ストックスクリーナーアプリを入手
14.01
4.09%
0.55
アフターアワーズ：
13.99
-0.02
-0.14%
前日終値:
$13.46
開ける：
$13.52
24時間の取引高:
23,909
Relative Volume:
0.29
時価総額：
$125.64M
収益：
-
当期純損益:
$-40.62M
株価収益率:
-0.7219
EPS:
-19.4076
ネットキャッシュフロー:
$-35.63M
1週間 パフォーマンス:
+3.32%
1か月 パフォーマンス:
-6.48%
6か月 パフォーマンス:
-17.59%
1年 パフォーマンス:
+22.63%
1日の値動き範囲:
$13.52
$14.21
1週間の範囲:
$12.40
$14.21
52週間の値動き範囲:
$6.27
$27.40
Promis Neurosciences Inc Stock (PMN) Company Profile
名前
Promis Neurosciences Inc
セクター
電話
416-847-6898
住所
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
14.01 | 121.60M | 0 | -40.62M | -35.63M | -19.41 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Promis Neurosciences Inc (PMN) 最新ニュース
ProMIS Neurosciences at Moody Capital conference: safety sets it apart By Investing.com - Investing.com Canada
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com Nigeria
ProMIS Neurosciences Inc. (NASDAQ: PMN) Share Price, PMN Stock News, PMN Share Price & Updates - Kalkine
ProMIS Neurosciences (PMN) Edges Up 0.24% to $12.56 as Shares Consolidate Between Support and ResistanceChannel Breakout - siam.in
ProMIS Neurosciences PMN310 shows early Alzheimer's promise - scanx.trade
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September - Yahoo Finance
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Revenue Estimate Trend - vinanet.vn
PMN310 shows dose-dependent reduction of amyloid-beta oligomers - scanx.trade
ProMIS (PMN) Earnings Update: The EPS Result Is Above Expectation in Latest Trading; Price Move: The Stock Records a 0.13% Increase in the Latest SessionEarnings Manipulation Risk - vinanet.vn
Q3 EPS Estimates for PMN Raised by Brookline Capital Markets - MarketBeat
ProMIS Neurosciences (PMN) Q2 2026 Update Highlights Strong Cash Position Amid High Valuation - GuruFocus
Maxim Group Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $35 - Moomoo
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Momentum Breakout Ideas - vinanet.vn
Roth Capital initiates coverage on ProMIS Neurosciences with Buy rating - scanx.trade
PMN Maintained by Guggenheim -- Price Target Raised to $100 - GuruFocus
Guggenheim Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $100 - Moomoo
ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside - TradingView
Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
ProMIS Neurosciences (PMN): Great Point group reports 7.66% beneficial stake - Stock Titan
Chardan Capital Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $33 - Moomoo
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ... By GuruFocus - Investing.com Canada
ProMIS Neurosciences Q2 Results: Cash Runway Extends To 2027 - scanx.trade
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlight - GuruFocus
Promis Neurosciences Q2 Earnings Call Highlights - MarketBeat
ProMIS Neurosciences (PMN) Climbs 2.00% to $14.79, Approaching Key Resistance at $15.53Turnaround Stocks - vinanet.vn
PROMIS NEUROSCIENCES ($PMN) Releases Q2 2026 Earnings - Quiver Quantitative
Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026 - Investing.com Canada
PMN: Interim phase I-B data for PMN310 showed no ARIA-E and strong biomarker signals, with cash runway through 2027 - TradingView
Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
ProMIS Neurosciences (PMN) gets 7.77% stake disclosure by Wellington fund - Stock Titan
ProMIS Neurosciences Inc. Q2 2026: Net loss $(11.73)M, Diluted EPS $(1.28) — 10-Q Summary - TradingView
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights - The Manila Times
ProMIS Neurosciences (PMN) extends cash runway with $70.1M PIPE amid higher R&D - Stock Titan
ProMIS Neurosciences (PMN): Wellington group discloses 7.77% ownership stake - Stock Titan
ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProMIS Neurosciences Inc expected to post a loss of $1.38 a shareEarnings Preview - TradingView
ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider at ProMIS Neurosciences (PMN) buys 2,280 common shares - Stock Titan
ProMIS Neurosciences Inc (PMN) Stock News Today - TradingKey
Promis Neurosciences (NASDAQ:PMN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Promis Neurosciences (PMN) Projected to Post Earnings on Thursday - MarketBeat
Janus Henderson Group PLC Acquires New Position in Promis Neurosciences $PMN - MarketBeat
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026 - The Manila Times
ProMIS Neurosciences (PMN) Shares Drop 8% as Stock Tests Key Support LevelETF AUM Growth - vinanet.vn
ADAR1 Capital Management LLC Buys Shares of 95,350 Promis Neurosciences $PMN - MarketBeat
Alzheimer Agent PMN310 Shows No ARIA-E in Six-Month Interim Analysis of Phase 1b AD Trial - NeurologyLive
PMN Maintains Buy Rating by Chardan Capital -- Price Target Rais - GuruFocus
Chardan raises ProMIS Neurosciences stock price target on trial data By Investing.com - Investing.com Canada
Chardan Adjusts Price Target on ProMIS Neurosciences to $33 From $20, Maintains Buy Rating - marketscreener.com
ProMIS Neurosciences (PMN) Reports Promising Interim Biomarker D - GuruFocus
Promis Neurosciences Inc (PMN) 財務データ
収益
当期純利益
現金流量
EPS
Promis Neurosciences Inc (PMN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kirwin Patrick D. | Director |
Apr 22 '26 |
Buy |
11.33 |
4,000 |
45,320 |
4,653 |
| Williams Eugene | Director |
Mar 05 '26 |
Buy |
24.40 |
2,000 |
48,800 |
12,397 |
| Williams Eugene | Director |
Mar 04 '26 |
Buy |
24.00 |
2,000 |
48,000 |
10,397 |
| Williams Eugene | Director |
Mar 02 '26 |
Buy |
22.53 |
1,000 |
22,530 |
7,397 |
| Williams Eugene | Director |
Mar 03 '26 |
Buy |
21.89 |
1,000 |
21,890 |
8,397 |
| Kaplan Johanne | Chief Development Officer |
Feb 19 '26 |
Buy |
15.35 |
1,629 |
25,005 |
3,941 |
| ABG Management Ltd. | 10% Owner |
Feb 03 '26 |
Buy |
12.13 |
700,741 |
8,499,988 |
943,090 |
| Milbury Max A. | Principal Accounting Officer |
Oct 03 '25 |
Buy |
0.49 |
30,392 |
14,929 |
45,389 |
0.88%
大文字化:
|
ボリューム (24 時間):